Product overview

Name Torin 2
Purity >98%
Description Potent, selective mTOR inhibitor
Write Your Own Review
You're reviewing:Torin 2
Rate this item:

Biological Data

Biological description Potent, selective and ATP-competitive mTOR inhibitor (IC50 = 2.1 nM and EC50 value = 250 pM for inhibition of cellular mTOR activity). Shows 800-fold selectivity over PI3K and >100-fold selectivity over ~400 other protein kinases. Shows potent antiproliferative activity. Causes apoptosis and autophagy and induces G0/G1 cell cycle arrest.

Solubility & Handling

Storage instructions +4°C
Storage of solutions Prepare and use solutions on the same day if possible. Store solutions at -20°C for up to one month if storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.
Shipping Conditions Stable for ambient temperature shipping. Follow storage instructions on receipt.
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >98%
Chemical name 9-(6-Amino-3-pyridinyl)-1-[3-(trifl uoromethyl)phenyl]-benzo[h]-1,6-naphthyridin-2(1H) -one
Molecular Weight 432.4
Molecular Formula C24H15F3N4O
CAS Number 1223001-51-1
PubChem identifier 51358113
SMILES O=C(C=C3)N(C5=CC=CC(C(F)(F)F)=C5)C2=C3C=NC1=CC=C(C4=CC=C(N)N=C4)C=C12
InChiKey GUXXEUUYCAYESJ-UHFFFAOYSA-N

References for Torin 2

References are publications that support the biological activity of the product
  • Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.

    Simioni et al (2014) Oncotarget 5(20) : 10034-47
  • Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

    Liu et al (2013) Cancer Res 73(8) : 2574-86
  • Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

    Liu et al (2011) J Med Chem 54(5) : 1473-80

3 Item(s)